These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427 [TBL] [Abstract][Full Text] [Related]
12. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
13. High clinical and morphologic response using Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267 [TBL] [Abstract][Full Text] [Related]
16. Phase 3 Trial of Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E; N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709 [TBL] [Abstract][Full Text] [Related]
17. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704 [TBL] [Abstract][Full Text] [Related]
18. Investigation of receptor radionuclide therapy with Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927 [TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377 [TBL] [Abstract][Full Text] [Related]
20. Long-Term Efficacy, Survival, and Safety of [ Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192 [No Abstract] [Full Text] [Related] [Next] [New Search]